Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14441137 | 0.86 | OPRM1 (0.49) | OPRM1POLBCYP3A4CYP2D6NPSR1 | |
| SCHEMBL11073259 | 0.81 | OPRM1 (0.57) | PDE4APDE4BPDE4CPDE4DOPRM1 | |
| SCHEMBL11093941 | 0.81 | OPRM1 (0.58) | PDE4APDE4BPDE4CPDE4DOPRM1 | |
| Ethylene SCHEMBL11073847 | 0.79 | OPRM1 (0.54) | PDE4APDE4BPDE4CPDE4DOPRM1 | |
| SCHEMBL1559063 | 0.78 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DOPRM1 | |
| SCHEMBL2288499 | 0.78 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DOPRM1 | |
| SCHEMBL735798 | 0.78 | MEN1 (0.57) | PDE4APDE4BPDE4CPDE4DOPRM1 | |
| SCHEMBL11706527 | 0.77 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DOPRM1 | |
| SCHEMBL1557899 | 0.77 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DOPRM1 | |
| Ethylene SCHEMBL11828563 | 0.75 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303846-B1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI SA (FR) | 2015-04-29 | — | — | EP | disclosed |
| EP-2303846-B1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI SA (FR) | 2015-04-29 | — | — | EP | disclosed |
| US-8541449-B2 | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-8541449-B2 | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | ROCK1, MYLK, ROCK2 | PDE4A 346/4885PDE4B 489/4885PDE4C 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.